ABSTRACT We report the establishment of human-human hybridomas producing monoclonal antibody of predefined antigenic specificity. The U-266 human myeloma cell line was incubated in the presence of 8-azaguanine, and a rapidly growing, 8-azaguanine-resistant, hypoxanthine/amethopterin/thymidine (HAT) medium-sensitive mutant line, U-266ARI, was selected. These cells were fused with lymphoid cells from uninvolved spleens removed at staging laparotomy from patients with untreated Hodgkin's disease who had been previously sensitized to the chemical allergen 2,4-dinitrochlorobenzene. Hybrid cell cultures growing in HAT medium were screened for IgG production. Positive cultures were selected and their supernatants were tested in a solid-phase radioimmunoassay for reactivity with dinitrophenyl hapten coupled to bovine serum albumin. Cultures producing specific antibody were subcloned and expanded, and their antibody products were shown to be monoclonal by biosynthetic labeling and sodium dodecyl sulfate/polyacrylamide gel electrophoresis.
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The production by Kohier and Milstein (1, 2) of mouse "hybridomas" capable of secreting specific monoclonal antibodies against predefined antigens has ushered in a new era in experimental immunology. Essentially all of the problems associated with heteroantisera are circumvented; the clonal selection and immortality of such hybridoma cell lines assure the monoclonality, monospecificity, and permanent availability of their antibody products. At the clinical level, however, the use of such antibodies would clearly be limited by the fact that they are foreign proteins. Chimeric hybridomas have been generated by fusing mouse myeloma cells with human immunoglobulin-producing cells (3) ; however, such hybrids tend to be unstable due to the progressive loss of human chromosomes. Permanent cultures of specific antibody-producing human B lymphocytes have been obtained by transformation with Epstein-Barr virus (EBV) (4) ; this method appears to be of limited practical applicability. We describe here a method by means of which we have been able reproducibly to obtain human monoclonal anti-2,4-dinitrophenyl (DNP) antibodies by fusing 2,4-dinitrochlorobenzene (DNCB)-primed human spleen lymphoid cells with human myeloma cells sensitive to hypoxanthine/amethopterin/thymidine (HAT) medium. In principle, this method should permit the generation of human monoclonal antibodies against a broad spectrum of predefined antigens.
MATERIALS AND METHODS
Human Myeloma Cell Line. A mutant cell line sensitive to HAT medium (5) was selected from the U-266 human myeloma cell line described by Nilsson et al. (6) (10) , including sensitization and later challenge with DNCB.
A single-cell suspension prepared from the spleen tissue was freed of erythrocytes and granulocytes by Ficoll/Hypaque gradient centrifugation (7, 8) , and the viable mononuclear cells were suspended in RPMI 1640 medium. Adherent cells were removed by incubation of the mononuclear cells in plastic dishes three times for 20 min each at 37°C and removal of the nonadherent cells after each incubation. The lymphocyte-enriched mononuclear cell suspensions thus obtained were then fused with the U-266AR1 human myeloma cell line.
Fusion. For fusion, 2 X 107 myeloma cells and 2 X 107 lymphoid cells were mixed, washed twice in RPMI 1640 medium, and then fused in 2.0 ml of 38% (wt/vol) polyethylene glycol at 37°C. After fusion, the cells were washed twice in warm (37'C) RPMI 1640 medium, suspended at a concentration of 106 cells per ml in RPMI 1640/15% FCS, and seeded in 0.2-ml samples in microtiter plates with flat-bottom wells (Falcon no. 3040, Oxnard, CA). Hybrids were selected by incubation in HAT medium containing 1 MuM hypoxanthine, 63 nM (+)-amethopterin, and 1.5 MM thymidine. HAT-resistant hybrids grew out within 8-14 days, but incubation in HAT medium was continued for at least 3-4 weeks.
Antibody Products. Screening for immunoglobulin production was performed with a solid-phase radioimmunoassay using 125I-labeled Staphylococcus aureus protein A as the detector. This procedure selectively detects IgG molecules.
Supernatants from cultures positive for staphylococcal protein A-binding IgG production were then tested in a radioimmunoassay for the presence of antibodies capable of binding specifically with high affinity to DNP conjugated with bovine serum albumin. Several anti-DNP antibody-producing cultures were detected by this procedure. Cells from such wells were cloned by the limiting dilution procedure, and cultures of the clone producing the highest level of specific anti-DNP antibody were expanded. 
RESULTS
The influence of cell density in the initial wells on the growth of hybrid cells was investigated in a preliminary experiment. Table 1 indicates that 2 X 105 cells per well was the optimal concentration both with respect to hybrid cell growth and IgG production.
Screening for anti-DNP antibody production revealed 3, 2, and 0 positive wells, respectively, in experiments with hybrid cells derived from the spleen cells of three successive patients. Cells from the positive wells were cloned under limiting dilution conditions. The five specific anti-DNP antibody-producing clones thus obtained were then expanded. At optimal hybrid cell concentrations, the amounts of immunoglobulin produced by these clones ranged between 3 and 11 gg/ml per day. The radioimmnnoassay data obtained with these anti-DNP antibodies at the time of initial screening, cloning, and clonal expansion are presented in Table 2 .
Production of IgE(X) by the parental U-266 myeloma cell line, as reported by Nilsson et al. (6) , was confirmed by NaDodSO4/polyacrylamide gel electrophoresis. The selected HAT-sensitive mutant of U-266 (the U-266AR1 cell line) was found to secrete somewhat lower levels of both the eand X chain products (Fig. 1) . Analysis of [14C]leucine-labeled immunoglobulins produced by hybrid clone H4D11 revealed the presence of a single additional light (NL) and heavy (,y) chain, confirming the monoclonality of-this antibody product (Fig.   1 ). 
DISCUSSION
The results reported here demonstrate that it is possible to obtain monoclonal human antibodies by fusion of a HAT-sensitive human myeloma cell line (U-266AR1) with antigen-primed lymphoid cells. Hybridization of human lymphoid cells with murine myeloma cells has been reported to result in hybridomas capable of secreting human immunoglobulin (3). However, such hybridoma cells are generally unstable due to progressive loss of human chromosomes; this problem seriously limits the use of mouse-human hybridomas for the production of monoclonal antibodies against predefined antigens. Another approach that has yielded monoclonal antibodies of human origin has been to transform human peripheral blood B cells with EBV and then to select and clone the EBV-transformed cells that produce antibodies against a defined antigen (4). This technique requires selection from presensitized human donors of B cells with the appropriate antigen-binding specificity, a requirement that would ethically exclude the use of many antigens. Production of antibody against sheep erythrocytes has also been reported (11) with cultures of human lymphocytes sensitized in vitro against sheep erythrocytes and simultaneously exposed to EBV, but antibody production was sustained for only a short time, usually less than 10 days.
The original U-266 myeloma cell line was reported to produce IgE(X) (6) ; that it still does so was confirmed in our preliminary studies. The monoclonality of the antibody produced by the cloned hybridomas was indicated by the presence of only a single new light and heavy chain in NaDodSO4/polyacrylamide gels of radiolabeled immunoglobulins. An advantageous Proc. Natl. Acad. Sci. USA 77 (1980) .1 1.
I () () () property of the U-266AR1 cell line is its rate of proliferation, which is about twice that of the parental U-266 cell line.
The lymphoid parental cells were obtained from the uninvolved spleens of patients with Hodgkin's disease. Many of these patients are known to have an impairment of cell-mediated immunity (10) , including failure to develop delayed cutaneous hypersensitivity responses to natural recall antigens or to DNCB. It is of interest that the first two patients, whose hybridized spleen cells produced anti-DNP antibodies, responded positively when challenged with DNCB, whereas the third patient, whose spleen cells failed to produce anti-DNP antibody, did not. It is conceivable that the abnormal immunologic reactivity of the spleen cells from patients with Hodgkin's disease may be of importance for successful hybridization with U-266AR1 cells. Immediately after fusion, the cell population is a mixture of autologous, semi-allogeneic, and allogeneic components, which would be expected to generate cytotoxic immune reactions of parental lymphoid cells against the myeloma cells and hybrids. With normal spleen cells, such reactions might impair the survival and subsequent outgrowth of the fused hybrids. It is thus possible that the impaired T-lymphocyte reactivity of cells from patients with Hodgkin's disease may have facilitated hybrid survival and growth.
Our screening procedure for immunoglobulin-producing hybrids used 125I-labeled staphylococcal protein A, which detects only IgG(yl, 7Y2, 74) and IgA(a2). It is thus quite possible that the total number of Ig-producing hybrids is considerably higher than that scored by this screening assay. In mouse hybridoma experiments, a significant fraction of antibody-producing clones secrete IgM. Thus, IgM-producing human hybridomas would also be expected. It would readily be possible to detect the production of human hybridomas of immunoglobulin classes other than IgG by modifying the screening assay to use radiolabeled heterologous antisera to whole human Ig or to specific types of heavy chains.
The only antigen used in the present study was DNCB. The ultimate importance of this method will depend on the spectrum of antigens against which human monoclonal antibodies can thus be produced. Experience with the mouse hybridoma technique indicates that the antibody spectrum is considerable, but this technique is also facilitated by the fact that immunization procedures can be optimized and that access to mouse spleen lymphoid cells is essentially unlimited. The usefulness of the human-human hybridoma procedure described in this report will be greatly enhanced if the antigen priming step can be carried out in vitro, thus making it possible to generate monoclonal antibodies to a broad spectrum of antigens.
Note Added in Proof. We have now succeeded in generating specific hybridoma antibodies against two additional antigens (sheep erythrocytes and a lipid fraction of endotoxin) after in vitro priming of spleen cells and peripheral blood mononuclear cells, respectively. The U-226AR1 myeloma cell line is now designated as Stanford University Biological Organism registry no. SKO-007.
